Evolutionary Tree Capital Management LLC Invests $2.26 Million in DexCom, Inc. (NASDAQ:DXCM)

Evolutionary Tree Capital Management LLC acquired a new stake in DexCom, Inc. (NASDAQ:DXCM) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 19,967 shares of the medical device company’s stock, valued at approximately $2,264,000. DexCom makes up about 2.3% of Evolutionary Tree Capital Management LLC’s portfolio, making the stock its 18th biggest holding.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in DXCM. Crewe Advisors LLC bought a new stake in shares of DexCom in the first quarter valued at about $29,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in DexCom in the 2nd quarter valued at approximately $25,000. DSM Capital Partners LLC acquired a new position in DexCom during the 4th quarter worth approximately $28,000. Riverview Trust Co bought a new position in shares of DexCom during the 1st quarter worth approximately $32,000. Finally, Sachetta LLC grew its stake in shares of DexCom by 255.2% during the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock worth $27,000 after acquiring an additional 171 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Stock Performance

NASDAQ DXCM opened at $70.43 on Friday. The stock has a market cap of $28.01 billion, a PE ratio of 45.44, a P/E/G ratio of 2.12 and a beta of 1.18. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.48 and a current ratio of 2.82. The firm has a 50-day moving average of $78.19 and a 200-day moving average of $109.54. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. The company had revenue of $1 billion during the quarter, compared to analysts’ expectations of $1.04 billion. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The business’s revenue was up 15.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.34 earnings per share. On average, sell-side analysts anticipate that DexCom, Inc. will post 1.69 EPS for the current year.

Insider Activity at DexCom

In other DexCom news, EVP Sadie Stern sold 426 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the transaction, the executive vice president now owns 75,451 shares in the company, valued at approximately $5,217,436.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the transaction, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at $5,217,436.65. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Michael Jon Brown sold 659 shares of DexCom stock in a transaction that occurred on Friday, June 28th. The shares were sold at an average price of $114.29, for a total transaction of $75,317.11. Following the completion of the sale, the executive vice president now owns 66,901 shares of the company’s stock, valued at $7,646,115.29. The disclosure for this sale can be found here. Insiders sold 2,483 shares of company stock worth $201,708 in the last ninety days. 0.30% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Wells Fargo & Company reduced their target price on shares of DexCom from $145.00 to $80.00 and set an “overweight” rating for the company in a report on Friday, July 26th. Stifel Nicolaus increased their price objective on shares of DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, August 23rd. Oppenheimer lowered their target price on DexCom from $150.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, July 26th. JPMorgan Chase & Co. lowered DexCom from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $145.00 to $75.00 in a report on Friday, July 26th. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $145.00 price target on shares of DexCom in a research note on Tuesday, July 23rd. Seven equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $112.25.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.